Meeting
2017 ASCO Annual Meeting
PEGylated human IL-10 (AM0010) monotherapy in refractory metastatic colorectal cancer.
Authors
Jeffrey R. Infante
Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN
Jeffrey R. Infante , Kyriakos P. Papadopoulos , Aung Naing , Karen A. Autio , Patrick Alexander Ott , Deborah Jean Lee Wong , Johanna C. Bendell , Todd Michael Bauer , Shubham Pant , Peter Van Vlasselaer , Gail Linda Brown , Martin Oft
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT02009449
Citation
J Clin Oncol 35, 2017 (suppl; abstr 3571)
DOI
10.1200/JCO.2017.35.15_suppl.3571
Abstract #
3571
Poster Bd #
194
Abstract Disclosures
Similar Posters
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Phase I study with pegylated human IL-10 (AM0010) alone or in combination with anti-PD-1 or FOLFOX-immune biomarker update.
First Author: Aung Naing
Poster
2017 Gastrointestinal Cancers Symposium
Phase 1b study with PEGylated human IL-10 (AM0010) with 5-FU and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC).
First Author: J. Randolph Hecht
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Amivantamab monotherapy in relapsed/refractory metastatic colorectal cancer: OrigAMI-1, an open-label, phase 1b/2 study.
First Author: Paul Eliezer Oberstein
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of trifluridine/tipiracil in combination with bevacizumab in older and younger patients with refractory metastatic colorectal cancer: A subgroup analysis of the phase 3 SUNLIGHT trial.
First Author: Julien Taieb